Abstract: Autoimmune B cells play a major role in mediating tissue damage in multiple sclerosis (MS). In MS, B cells are believed to cross the blood-brain barrier and undergo stimulation, antigen-driven affinity maturation and clonal expansion within the supportive CNS environment. These highly restricted populations of clonally expanded B cells and plasma cells can be detected in MS lesions, in cerebrospinal fluid, and also in peripheral blood.
Introduction
Those of us engaged in biomedical research understand well the slow pace of discovery, the disappointments, and the myriad constraints that complicate our lives. For scientists who are also clinicians, the joys of clinical medicine are an ever-present draw and a pull away from the laboratory; rewards of clinical work are reliable, providing the opportunity to help 10 or maybe 20 patients in a busy day, to experience a series of professional successes before retiring each night, and to be spared the disappointment of rejected manuscripts, unfunded grants, or most crushingly when months or even years of work lead to less than expected progress.
These downsides of a career in research are overwhelmed, however, by the thrill of learning something that has never been known before, and especially by the joy of making a medically useful discovery, something that happens, if one is fortunate, perhaps a few times over the course of a career. For those of us involved in the B cell story in multiple sclerosis (MS), such a happening occurred on a crisp Friday afternoon in northern California; it was September 2006, and the event was the unblinding of the phase II anti-CD20 rituximab (RTX) study ( Figure 1 ). 1 Looking back, the joy was twofold. First, we saw evidence of a potentially powerful new approach for therapy of relapsing MS. Second, despite this success, it was also evident that our scientific rationale behind the clinical testing of RTX for MS was almost certainly incorrect. Looking back, this was the best possible result of a translational research experiment. We identified a novel approach that appeared to offer significant benefit for patients, and yet the data also sent us back to the laboratory in new and unexpected research directions. Indeed, the rubber meets the road when ideas born in the laboratory are formally road-tested at the bedside, and when data from real-life patients send us back to the laboratory armed with new hypotheses. Translational medicine is most effective when information flow is bidirectional, linking the laboratory with the clinic.
The early days
An early experience occurred in the late 1970s during my neurology residency. A number of us were sitting around a conference room on the ninth floor of the old Vincent Burnham building at Massachusetts General Hospital with our chair of neurology, Raymond D. Adams. A postdoctoral fellow from Massachusetts Institute of Technology (MIT) was presenting some work in experimental autoimmune encephalomyelitis (EAE) induced by myelin basic protein (MBP). Adams noted, with a touch of sarcasm, that the paralysis observed in the rodents likely resulted from peripheral nerve, and not central nervous system (CNS), disease. Indeed, he emphasized that the pathology of EAE and MS were quite different ( Figure 2 ). In particular, T cell-mediated acute EAE models in mice were dominated by an inflammatory panencephalitis with relatively sparse demyelination, unlike the primary macrophage-mediated demyelinating pathology typical of human MS. This experience motivated me to dig deeper into the comparative pathology of the two conditions, and eventually to embark on a long-term effort to model MS-like pathology in the laboratory.
Developing a better disease model
This effort began in partnership with Norman Letvin (1949-2012), a medical school classmate and postdoctoral lab mate whose interest had gravitated toward the immunology of non-human primates, and who would soon become director of the Harvard-affiliated New England Primate Research Center in Massachusetts, where he would develop new reagents to tackle this problem, and also discover the simian immunodeficiency virus in the process. We began immunizing different species of non-human primates to search for pathologies that closely mimicked MS. 2 We were particularly hopeful that a model could be generated in marmosets, and in particular the New World marmoset Callithrix jacchus (C. jacchus), a small primate approximately the size of a guinea pig (400 mg) but with a remarkable and defining characteristic, unique among primates. C. jacchus pregnancies are typically multiple, with gestation of several non-identical embryos at a time. Each fetus shares a common fetal blood supply, leading to establishment of a permanent, stable, lifelong bone marrow chimerism among fraternal twins or triplets. We found that this chimeric state, as predicted, permitted the transfer of T lymphocytes from one sibling to another without eliciting any immune response (alloresponse) in the recipient. These data set the stage, at least in theory, for the adoptive transfer of encephalitogenic T cells in a species phylogenetically close to humans, analogous to earlier experiments in inbred mice that were critical for defining the immunology of murine EAE. If we could produce an MS-like condition in C. jacchus, we'd have the necessary tools to dissect its immune architecture. Indeed, after several years of starts and stops, this was successfully accomplished by Luca Massacesi in 1995. 3 The key event in this discovery, which eluded us before Luca's arrival, was the creative use of different immune adjutants. 4 Following a single immunization with a myelin extract in incomplete Freund's adjuvant, and later with myelin oligodendrocyte glycoprotein (MOG), animals developed a mild relapsing-remitting disease, and an acute pathology characterized by large concentric areas of macrophagemediated demyelination with relative axonal sparing and foci of remyelination; the myelin membrane was destroyed and reconstituted into vesicular fragments (Figure 3 ), a pattern termed vesicular demyelination and previously described in MS lesions by John Prineas. 5 The day that we reviewed the pathology slides from C. jacchus EAE we literally gasped-our first eureka moment. We had replicated the MS-like pathology that we had sought for a decade.
However, when we adoptively transferred MOGreactive T cell clones from an immunized C. jacchus animal into a chimeric sibling, we replicated the acute murine pathology of panencephalitis but not the distinctive MS-like pathology of vesicular demyelination. 3 The explanation for this apparent conundrum was quickly solved by another superb scientist and postdoctoral fellow at the time, Claude Genain. Claude discovered that only by the co-administration of encephalitogenic T cells plus pathogenic Abs could the MS-like demyelinating phenotype be reconstituted. This led us to focus on the concept that an MS-like, demyelinating lesion required both pathogenic T cells plus autoantibodies; the autoantibodies alone were nonpathogenic, presumably because they required encephalitogenic T cells to open the blood-brain barrier (BBB) and permit their passage into the CNS. 6, 7 Our confidence that these mechanisms were operational in MS was strengthened by older literature in guinea pig optic neuritis first described by Appel and Bornstein in 1964, 8 and later by Linington, Olssen, and Wekerle in work with rat EAE models. 9, 10 In 1999 we completed a deeper dive into the immunohistochemistry of the lesion with the superb experimental neuropathologist Cedric Raine, revealing the presence of bound Abs in the demyelinated lesions of C. jacchus that recognized the immunizing antigen (Ag) MOG. However, when we then turned our collective attention to human MS tissue, we found that deposited Abs were also bound to the myelin membrane but had specificities that were far more diverse than in EAE. 11, 12 This suggested that the humoral immune response in chronic MS is composed of autoantibodies with multiple specificities, and that in consequence a highly focused immunotherapy is unlikely to be successful.
Back to the bedside
Given the heterogeneous nature of the antibody (Ab) repertoire associated with myelin destruction in MS, it became clear that targeting any specific protein or epitope was a dubious therapeutic strategy. Thus we turned to methods that could deplete or inactivate a broad range of Abs, plasma cells, or perhaps their progenitors, B lymphocytes. The first two options were not feasible with available therapeutics, and we had previously found that indiscriminate Ab removal via plasmapheresis had little meaningful effect on chronic MS, 13, 14 thus our thoughts turned to B cell-based therapy and specifically the anti-CD20 monoclonal Ab RTX.
RTX was synthesized by Bill Rastetter at Idec Pharmaceuticals in 1986. IDEC entered into a codevelopment partnership with Genentech in 1995, and two years later RTX, marketed as Rituxan, received Food and Drug Administration (FDA) approval for treatment of B cell lymphoma. In 2001, I began discussions with Genentech around RTX therapeutics for MS after our failed application to the National Institutes of Health (NIH), championed by Claude Genain with Michael Racke and Nancy Monson at University of Texas Southwestern Medical Center (UT Southwestern) left us little hope that public resources could be found to support this trial. The referee comments from the application were dismissive, reflecting profound skepticism in the proposition that humoral immune mechanisms might be central to MS pathogenesis. Across much of academia at the time, MS was dominated by concepts of T cell mediation, analogy to murine EAE models, and a belief that CNS immunoglobulins (Igs), including oligoclonal bands (OCBs), represented meaningless, "nonsense" Abs. 15 The field was simply not ready.
Industry proved to be a more flexible, and less riskaverse, partner. Discussions with Genentech progressed well, although it was the company's belief that our chance of success was "less than 15%." Even if one accepted that autoantibodies were responsible for MS, a B cell-based therapy would not immediately knock down Ab production by long-lived plasma cells. Their experience with RTX indicated that IgG Ab levels were largely unchanged following treatment, although lower-affinity IgM was modestly reduced by approximately 15%. At least in theory, one would need many years of treatment to reduce circulating levels of Ig. Our original plan was to begin with a placebo-controlled phase IIB clinical trial of two courses of RTX spaced six months apart, and a primary endpoint at 12 months, or six months after the final infusion. However, the FDA balked at this design, advising us that it was, in their view, unethical to maintain a group of active relapsing MS patients on placebo therapy for one year. In response to these concerns the trial was scaled back; fewer patients would be enrolled, only a single course of RTX would be administered, and the primary endpoint would be measured at six months. Our prospects for success seemed ever dimmer.
As described in the introduction, when the data were unblinded, we learned that there was a dramatic and almost immediate 91% reduction in gadoliniumenhancing magnetic resonance imaging (MRI) activity (the primary endpoint) plus a significantly reduced rate of new relapses. 1 This was our second eureka moment. In addition to the effect size, the rapid-onset of the benefit conferred by RTX was possibly the most stunning aspect of the trial. Because the clinical effects happened so quickly they was almost certainly not due to any reduction of long-lived Abs, but were more likely to be explained by some direct effect on B cells themselves. In many respects, this was the best of all possible results for a clinical experiment. The data were extremely positive, raising hope that an impactful new approach to MS therapy would result, but also perplexing, sending us back to the laboratory with information that the underlying hypothesis behind the clinical trial was almost certainly wrong. We returned to the laboratory with a new focus on B cell biology.
The multifunctional B cell B cells are extremely diverse members of the universe of adaptive immunity. Although targeting of autoantibodies provided the original conceptual framework for testing RTX in relapsing MS, the resulting data made it likely that the robust efficacy was somehow related to a direct effect on B cells themselves. 16 B cells have numerous effector functions independent of their differentiation from Ab-secreting plasma cells (Figure 4) . B cells are highly effective Ag-presenting cells (APCs), but unlike other conventional APCs that are promiscuous Ag presenters, B cells are most efficient in presenting Ag that is initially recognized by their surface B cell receptor (BCR), i.e. the clonally specific Ig molecule. Thus they can be viewed as extremely selective APCs. Ag initially bound to surface BCR is internalized, complexed in endosomes with class II major histocompatibility complex (MHC) molecules, and returned to the surface for Ag presentation to T cells. B cells are also highly motile, and in secondary lymphoid structures they play a role in Ag shuttling, a process in which Ag is grabbed from macrophages by B cells via the BCR and transported to follicular dendritic cells (DCs), another class of APCs. Through secretion of cytokines B cells can also regulate, as bystanders, various effector immune functions mediated by both B and T cells. Some B cells support pro-inflammatory function through secretion of tumor necrosis factor alpha (TNFα) and lymphotoxin, whereas a different interleukin (IL)-10-producing B cell population has a regulatory, anti-inflammatory, role. Interestingly, MS B cells may be inherently polarized toward a proinflammatory functional phenotype. 17 As noted above, the rapid response of B cell depletion therapy on focal disease activity in relapsing MS indicated that the mechanism of action was likely not, as initially hypothesized, through inhibiting autoantibodies but more likely by blocking B cell APC function and subsequent T cell activation, or perhaps via bystander effects on adaptive immunity. However, the potential inhibition of an as-yet unidentified autoantibody in MS cannot be completely excluded; Abs of the Ig4 isotype class are often synthesized by short-lived plasmablasts, and in IgG4-mediated autoimmune diseases rapid clinical responses to RTX can be associated with a rapid decline in autoantibody titers. 18 B cell development begins in the bone marrow and proceeds through stages of pro-and pre-B cells prior to exiting into the circulation as naïve, Ag-inexperienced B cells. The vast majority of B cells are located in follicles in secondary lymphoid tissues, including lymph nodes and spleen, and in mucosal sites. Binding of Ag through the BCR triggers activation, proliferation and If B cells residing in pathogenic niches, such as the CNS in MS, or synovium in rheumatoid arthritis (RA), are relatively protected from anti-CD20 therapy, then how does the treatment work? The most likely explanation is that sustained depletion of circulating B cells, which in autoimmune disease likely includes recirculating, restimulated memory B cells destined to return to the target tissue, prevents their re-entry into focal white matter regions in MS or joint tissue in RA. 19 Technology moves faster than clinical research It took 18 months for the RTX data to find their way into final print, 1 and by this time, to the surprise and disappointment of many, the prospects for advancing to phase III clinical trials of RTX were dead. The reasons for this were multiple but included complex governance of the RTX franchise between the two participating pharmaceutical companies, Biogen/Idec and Genentech; the development of a new fully humanized anti-CD20 monoclonal Ab, ocrelizumab (OCR) by Genentech; and Roche's acquisition of Genentech in 2009. A plan was put forward to no longer pursue RTX but instead to initiate an OCR phase IIB trial.
Different monoclonal Abs are not necessarily biologically identical even if they target the same molecule; this is certainly the case for Abs that target CD20. RTX and OCR target different epitopes of CD20 and kill B cells through different cytolytic pathways. RTX has stronger complement-dependent cytotoxicity (CDC) and less Ab-dependent cell-mediated cytotoxicity (ADCC), whereas the converse is true for OCR. Greater ADCC activity by OCR results from a higher affinity of Fc binding to the Fc gamma receptor IIIa (FcγRIIIa) on host natural killer (NK) cells. Importantly, FcγRIIIa genotypes also influence ADCC; at position 158, a substitution of valine for phenylalanine increases affinity for the Fc receptor and ADCC activity. The dose of Ab used, and the frequency of administration, may also influence ADCC activity. These differences between RTX and OCR may help to explain a complication observed in a trial of OCR as add-on therapy for RA in which several serious opportunistic infections developed in older Asian RA patients treated with high doses of OCR. 20 This complication in the OCR trial was quite unexpected, as no safety signal of this type had been noted in the nearly 200,000 RA patients treated with RTX as add-on therapy. 21 Although the RA trial of OCR was halted, the MS phase II trial of low-dose OCR as monotherapy proceeded, and when the results were unblinded, a robust treatment response identical to that found for RTX was observed. 22 Furthermore, no adverse safety signal was observed. Also important, our hope that OCR, a fully humanized Ab, would produce a lower incidence of infusion reactions compared with the chimeric (mouse-human) RTX was dramatically confirmed, making OCR a far more attractive agent for chronic use. All involved breathed a deep collective sigh of relief as we advanced to the pivotal phase III clinical trials.
Additional insights from the phase II trials
We had observed in the original RTX study in MS that focal disease activity remained reduced even after B cells had returned to the peripheral blood (PBL). This point was driven home in a preliminary open-label, open extension phase of the OCR phase II study. After four courses of treatment with OCR, MRI and clinical disease activity remained quiescent 18 months after the last dose. Equally important, in the phase II studies no evidence of rebound was present at any time point. These data suggested that anti-CD20 treatment might reset the immune system in some way, and confer protection against the development of new focal MS lesions beyond the period of B cell depletion. Studies of PBL in RTX-treated individuals indicated that, following repletion, there are persistent changes in both B and T cell subpopulations that could, at least in theory, promote immune homeostasis and reduce proinflammatory responses. Repleting B cells express predominantly naïve and immature (CD5, CD38hi) phenotypes; 23 proinflammatory Th1 and Th17 T cells are decreased; 17 and CD25+FoxP3+ regulatory T cells are increased. 24 Reductions in proinflammatory immune cells are also present in cerebrospinal fluid (CSF), with reduced numbers of T and B cells 25, 26 and a predominance of resting, CD19-bright, B cells. 27 Another surprise-CD20+ T cells For more than 20 years there have been scattered reports that some human T cells bear surface CD20 Ag, but these reports have generally relied on uncertain methods or study of abnormal, e.g. malignant, T cells. Recently, Christian von Büdingen led an effort that produced unequivocal evidence that CD20 T cells indeed exist in the healthy human circulation. 28 This heterogeneous population, representing about 7% of total mature circulating T cells, is composed of numerous T cell subsets including both CD4 helper and CD8 cytotoxic T cells as well as well as naïve and various memory T cell populations. Notably, CD20+ T cells have a lower surface density of CD20 compared to B cells, hence the designation CD3, CD20dim, but nonetheless the vast majority of these cells are depleted from the peripheral circulation with anti-CD20 therapy. Thus it remains possible, and would certainly be ironic if true, that the effects of anti-CD20 therapy on MS results from elimination of a pathogenic CD20-positive T cell population.
Back to the bench
In a series of remarkable experiments, Scott Zamvil's laboratory has clarified how B cells functioning as APCs, and in the absence of any contribution of Ab, might lead to MS. His laboratory constructed mixed bone marrow (BM) chimeric mice containing B cells that were selectively deficient in expression of class II major histocompatibility complex (MHC II) molecules; other APCs, including DCs and monocytes, expressed MHC II normally. Following immunization with the extracellular region of mouse MOG, or with an immunodominant p35-55 MOG peptide, BM chimera mice lacking MHC II on B cells developed EAE normally. However, in response to immunization with recombinant human MOG, these mice were entirely resistant to EAE induction, and susceptibility could not be restored by administration of MOG Ab. 29 How can one interpret the finding that B cells competent to serve as APCs were absolutely required for EAE against human-but not against murine-MOG? It is likely that this B cell dependence can be attributed to a single amino acid change in the immunodominant region of MOG, e.g. a substitution of proline in place of serine at position 42 in human MOG. In a second series of experiments, Zamvil created transgenic mice that express surface MOG-reactive Ig on their B cells but could not secrete Ab. When crossed with a transgenic MOG-reactive T cell line, progeny developed spontaneous opticospinal EAE, associated with Th17 polarization, B cell activation, and formation of ectopic germinal centers in the meninges (see below), all in the absence of secreted Ab. These experiments provide unequivocal data that B cell APC function, in the absence of autoantibodies, are sufficient to promote T cell activation and an MS-like disorder.
In EAE, B cells tend to be involved as APCs when the immunization regimen employs whole myelin proteins such as human MOG (hMOG), but not when myelin peptides (e.g. p35-55 MOG) are used. Peptide immunization models are B cell independent because the BCR that binds mostly conformational rather than short linear epitopes is not involved in Ag capture. 30, 31 Interestingly, in EAE induced by whole MOG protein, B cell depletion is protective, but in MOG peptide EAE, B cell depletion worsens disease severity, probably by depleting IL-10-secreting regulatory B cells. 32 In humans, a recently published trial of atacicept, a decoy receptor for the B cell growth factors B cell activating factor (BAFF) and a proliferationinducing ligand (APRIL), paradoxically worsened MS, possibly by altering regulatory B cell tone. 33 These cautionary data emphasize that B cell depletion can be deleterious in some situations, and they also highlight the potential clinical relevance of information gleaned from EAE even when the models are imperfect representations of human MS.
Thus, B cells can be proinflammatory or regulatory, and the predominance of one or another function is a critical determinant of the outcome of an ongoing immune response. Clearly what is needed is to better understand B cell biology as it relates specifically to MS. One unbiased approach to this problem is through genetics and functional genomics. Gene variants that are expressed by B cells comprise an important component of the 110 variants thus far known to be associated with inherited risk for MS ( Figure 6 ). 34, 35 Similarly, a number of functional changes in B cells have been described in MS patients, including changes in cytokine profiles indicating an inherent proinflammatory bias, and a defect in inducing B cell tolerance in the PBL. 36 
Identifying and tracking culprit B cells
In addition to modeling B cell mediation in EAE models, another approach to understanding the role of B cells in MS is to dissect the molecular properties of activated B cells directly in people with MS. BCRs are heterodimeric proteins with the Ag-binding portion formed by the variable regions of heavy and light chains. With respect to Ag-recognition, the heavy chain variable region (VH) is generally believed to play the primary role; VH results from the splicing of three gene segments into a mature transcript; one copy of a variable (V), diversity (D), and joining (J) gene segment. 37 V, D, and J genes exist as multiple copies in each genome, contributing significantly to the diversity of Ab transcripts. Most Ab diversity is generated by variation in how the gene segments splice together, and especially by somatic mutations in the complementarity determining regions (CDR) of V genes that shape the Ab response. 38 Following Ag contact in secondary, and possibly also in ectopic, lymphoid tissues, BCRs undergo somatic diversification as their phenotype advances from naïve to memory B cells, and then to Ab-secreting plasmablasts and plasma cells. We first reported in 2010 through genomic analysis of monozygotic twins that the propensity of B cells to select some members of V gene families over others is highly heritable, but that the clonal repertoire of BCR molecules expressed by any individual is stoichastic in origin and not influenced by differences in the architecture of germline genes. 39, 40 The von Büdingen laboratory has established an effort to probe the clonal nature of B cells expressed in the CNS, and understand how these relate to the PBL compartment. As expected from earlier work, sequencing of IgG-VH repertoires in MS patients revealed that CSF B cells represent a clonally restricted population that had undergone highly selective activation and affinity maturation within the CNS compartment. With parallel sequencing of many thousands of IgG-VH transcripts per sample, it was possible to construct lineage trees representing clonally related CSF B cells defined by their BCRs, and identify clonally related BCR sequences from PBL in the same individual. Results revealed a deep connection of these highly selected, clonally related B cells between the CSF and PBL compartments ( Figure  7) . 41, 42 Furthermore, when CSF IgG-VH sequences were matched with mass-spectrometric proteomic analyses of isoelectric focused (IEF) CSF IgG, remarkably the proteomic data and IgG-VH transcripts matched. 43 Most peptides sequenced from OCBs could be shown to map to CSF-derived IgG-VH sequences, and furthermore in a given individual different bands comprising the OCBs were shown to be clonally related; i.e. they belong to the same BCR lineage tree. 41, 43, 44 Thus there is evidence for ongoing stimulation and maturation to clonally restricted Ab-expressing B cells occurring primarily inside the CNS compartment. In some individuals, B cells participating in OCB production can also be identified in PBL; these cells appear to migrate across the BBB and may also undergo further Ag stimulation in the periphery. 42, 44 Thus OCB are not merely the terminal result of a focused immune response in MS but represent a component of active B cell immunity that is dynamically supported on both sides of the BBB.
Although it is unclear where in the periphery activation and/or SHM of B cells responding to brain Ags might occur, recent data from Kevin O'Connor's group suggests that draining cervical lymph nodes represent one such potential site. 45 Returning to the inherited nature of gene segment usage by BCRs, our work in CSF, 41, 42, 44 and that of others studying CSF 46 and brain tissue 47 clearly show that the activated B cell clones in CNS of MS patients display a bias in terms of increased usage of members of the IgG VH4 family. These data raise the possibility that even more selective therapies based on targeting restricted populations of B cells defined by their surface Ab receptors could be effective.
B cells and progressive MS
As discussed earlier, the anti-CD20 therapies eliminate mostly circulating B cells, leaving B cells in secondary lymphoid organs and other sites largely unaffected. This feature could account for their favorable safety profile, but at least in theory could also pose a challenge to effectively treating progressive MS. 48 If established B cell nests residing in lymphoid follicle-like structures in the meninges are drivers of a chronic neurodegenerative process that ultimately results in progressive MS, 49 anti-CD20 therapy would likely fail to deplete B cells from these sites. This resistance of B cells in protective niches could explain the relatively meager response of RTX in primary progressive MS, 50 and our observation that individuals with relapsing MS can evolve to secondary progressive MS despite ongoing RTX treatment. Of course, it is also possible that long-lived, CD20-negative plasma cells and their Ab products play some role in progressive MS. We, and others, have limited evidence that OCBs can persist in the CSF even after chronic treatment with RTX, indicating that aberrant humoral immune responses have not been eliminated from the CNS. Targeting resident CNS B cell populations might require development of modified anti-CD20 monoclonal Abs that can disrupt protective niches, 51 or penetrate the BBB more effectively, for example, by modifying the Ab with a ferritin shuttle. Another area of great promise is to develop small molecules that inhibit critical B cell signaling pathways. 52 The first generation of B cell inhibitors have now been developed, ibrutinib 53 and idealisib; 54 both interact with the phosphoinositide (PI)3 kinase pathway downstream from BCR signaling, but whether either can cross the BBB effectively remains to be determined.
Conclusions
Looking back to that distant seminar room in Boston, it would have been impossible to imagine that 35 years later B cells would rest, arguably, at the epicenter of MS immunology. The B cell saga in MS has provided a cornucopia of surprises, thrilling insights, several disappointments, numerous still-to-be-solved conundrums, and also a few generic lessons. Foremost among the latter is the importance of road-testing ideas developed in the laboratory in real-life clinical situations, and vice versa. It argues for the essential role of clinician-scientists who walk the walk between these two worlds. 28 Finally, the long path from conception, to an initial clinical suggestion of efficacy, to completing the definitive clinical trials amply demonstrates, as many have previously noted, the bumpy and uncertain road that accompanies forays between academia and industry, a bidirectional process that must be made more efficient if we are to effectively translate new discoveries into treatments and cures for our patients.
There are too many people to thank here, so I will close by thanking the Multiple Sclerosis International Federation and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) for this singular honor, which I accept on behalf of so many others who have contributed to this story, shared with me the joys of watching it unfold, and await, as I do, its next chapter.
